Kym­ri­ah gets speedy re­views in US and EU as No­var­tis looks to swift­ly ex­pand CAR-T in­di­ca­tions

Equipped with da­ta to di­rect­ly com­pete with Gilead’s $GILD CAR-T, No­var­tis has se­cured promis­es of quick re­views of Kym­ri­ah for a sec­ond in­di­ca­tion in both the Unit­ed States and Eu­rope.

The Swiss drug­mak­er $NVS start­ed the day with news that the FDA has grant­ed pri­or­i­ty re­view to Kym­ri­ah in adult pa­tients with re­lapsed or re­frac­to­ry dif­fuse large B-cell lym­phoma (DL­B­CL) who are in­el­i­gi­ble for or re­lapse af­ter au­tol­o­gous stem cell trans­plant. That’s some­thing Yescar­ta goes af­ter, and marks a new tar­get for Kym­ri­ah af­ter B-cell acute lym­phoblas­tic leukemia.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.